Bioprocess engineering issues that would be faced in producing a DNA vaccine at up to 100 m3 fermentation scale for an influenza pandemic.
The risk of a pandemic with a virulent form of influenza is acknowledged by the World Health Organization (WHO) and other agencies. Current vaccine production facilities would be unable to meet the global requirement for vaccine. As a possible supplement a DNA vaccine may be appropriate, and bioprocess engineering factors bearing on the use of existing biopharmaceutical and antibiotics plants to produce it are described. This approach addresses the uncertainty of timing of a pandemic that precludes purpose-built facilities. The strengths and weaknesses of alternative downstream processing routes are analyzed, and several gaps in public domain information are addressed. The conclusion is that such processing would be challenging but feasible.
Hoare
Mike
M
The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Torrington Place, UK.
Levy
M Susana
MS
Bracewell
Daniel G
DG
Doig
Steven D
SD
Kong
Simyee
S
Titchener-Hooker
Nigel
N
Ward
John M
JM
Dunnill
Peter
P
D000327:Adsorption; D001698:Biomedical Engineering / Q000379:methods; D019149:Bioreactors; D001709:Biotechnology / Q000379:methods*; D002626:Chemistry, Pharmaceutical; D002845:Chromatography; D004196:Disease Outbreaks / Q000517:prevention & control*; D004926:Escherichia coli / Q000235:genetics; D005285:Fermentation; D005590:Fractional Precipitation; D006358:Hot Temperature; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007252:Influenza Vaccines / Q000235:genetics / Q000302:isolation & purification*; D007251:Influenza, Human / Q000453:epidemiology* / Q000517:prevention & control*; D010957:Plasmids / Q000235:genetics / Q000302:isolation & purification; D014462:Ultrafiltration; D019444:Vaccines, DNA / Q000235:genetics / Q000302:isolation & purification
D007252:Influenza Vaccines; D019444:Vaccines, DNA